Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 7/20 | 0.53 |
| ▸ | MMP2 | P08253 | 9/20 | 0.52 |
| ▸ | MMP9 | P14780 | 8/20 | 0.52 |
| ▸ | MMP13 | P45452 | 7/20 | 0.52 |
| ▸ | MMP8 | P22894 | 5/20 | 0.52 |
| ▸ | MMP3 | P08254 | 4/20 | 0.52 |
| ▸ | MMP14 | P50281 | 3/20 | 0.52 |
| ▸ | MMP16 | P51512 | 2/20 | 0.52 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.52 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | BMP1 | P13497 | 2/20 | 0.44 |
| ▸ | MMP7 | P09237 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6903460 | 0.79 | MMP1 (0.53) | MMP1MMP2MMP9MMP13MMP8 | |
| SCHEMBL5243658 | 0.77 | MMP1 (0.56) | MMP1MMP2MMP9MMP13MMP8 | |
| SCHEMBL7537818 | 0.75 | MMP9 (0.62) | MMP1MMP2MMP9MMP13MMP8 | |
| SCHEMBL7537813 | 0.75 | MMP9 (0.62) | MMP1MMP2MMP9MMP13MMP8 | |
| SCHEMBL7534320 | 0.74 | MMP9 (0.53) | MMP1MMP2MMP9MMP13MMP8 | |
| SCHEMBL7534325 | 0.74 | MMP9 (0.53) | MMP1MMP2MMP9MMP13MMP8 | |
| SCHEMBL231737 | 0.74 | MMP1 (0.55) | MMP1MMP2MMP9MMP13MMP8 | |
| SCHEMBL1133744 | 0.74 | MMP8 (0.81) | MMP1MMP2MMP9MMP13MMP8 | |
| SCHEMBL1133869 | 0.74 | MMP8 (0.65) | MMP1MMP2MMP9MMP13MMP8 | |
| SCHEMBL7532678 | 0.73 | MMP13 (0.51) | MMP1MMP2MMP9MMP13MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2671082-A2 | METHODS AND COMPOSITONS RELATING TO INHIBITION OF IGF-1R | Amgen Inc. (US) | 2013-12-11 | — | — | EP | disclosed |
| WO-2012106556-A2 | METHODS AND COMPOSITONS RELATING TO INHIBITION OF IGF-1R | AMGEN INC. (US) | 2012-08-09 | — | — | WO | disclosed |
| EP-2334701-A2 | FULLY HUMAN ANTIBODIES TO HIGH MOLECULAR WEIGHT-MELANOMA ASSOCIATED ANTIGEN AND USES THEREOF | University of Pittsburgh of the Commonwealth System of Higher Education (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-2257572-A1 | HUMAN ANTI-MESOTHELIN MONOCLONAL ANTIBODIES | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2010068923-A2 | AGENTS THAT SELECTIVELY INHIBIT CD25 ON DENDRITIC CELLS OR T CELLS AND THEIR USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010045495-A2 | FULLY HUMAN ANTIBODIES TO HIGH MOLECULAR WEIGHT-MELANOMA ASSOCIATED ANTIGEN AND USES THEREOF | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2009120769-A1 | HUMAN ANTI-MESOTHELIN MONOCLONAL ANTIBODIES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-10-01 | — | — | WO | disclosed |
| EP-1924604-A1 | HUMAN MONOCLONAL ANTIBODIES THAT SPECIFICALLY BIND IGF-II | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1660127-A4 | ANTIBODIES TO C-MET | PFIZER PROD INC (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1476185-A4 | ANTIBODIES TO CD40 | PFIZER PROD INC (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1660127-A1 | ANTIBODIES TO C-MET | Pfizer Products Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005030124-A2 | ANTIBODIES TO M-CSF | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005016382-A1 | ANTIBODIES TO C-MET | PFIZER PRODUCTS INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| EP-1483268-A2 | INDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2004-12-08 | — | — | EP | disclosed |
| EP-1476185-A2 | ANTIBODIES TO CD40 | Pfizer Products Inc. (US) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003040170-A9 | ANTIBODIES TO CD40 | PFIZER PROD INC (US) | 2004-06-10 | — | — | WO | disclosed |
| EP-1399483-A2 | ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR | PFIZER INC. (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003074529-A2 | iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003040170-A2 | ANTIBODIES TO CD40 | PFIZER PRODUCTS INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2002053596-A2 | ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR | PFIZER INC. (US) | 2002-07-11 | — | — | WO | disclosed |